Effect of ramipril on the incidence of diabetes

Article Abstract:

A prospective trial study for the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) was conducted to evaluate whether ramipril reduces the risk of diabetes in people who have impaired fasting glucose levels or impaired glucose tolerance but who are at low risk for cardiovascular events. Among persons with impaired fasting glucose levels or impaired glucose tolerance, the use of ramipril for 3 years does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycemia.

Patient outcomes, Drug therapy, Diabetes, Diabetes mellitus, Drug overview

---

ACE inhibition in cardiovascular disease

Article Abstract:

Many patients with risk factors for heart disease may benefit from ACE inhibitors. ACE inhibitors block the activity of angiotensin II. This is a natural substance in the body that has a beneficial effect provided that it is not produced in excess amounts. The first ACE inhibitor was developed in 1977 but by the 1980s, it was clear that they had many actions beyond their ability to lower blood pressure. They seem to protect the heart, kidneys, and blood vessels from long-term activation of the renin-angiotensin-aldosterone system.

Health aspects, Editorial

---

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Article Abstract:

The ACE inhibitor ramipril appears to reduce the risk of heart disease in people with diabetes or pre-existing blood vessel disease. Researchers randomly assigned 9,297 people who had no evidence of heart disease but had diabetes or blood vessel disease to take ramipril or a placebo for an average of five years. Those who took ramipril had a lower risk of death, heart attack, heart failure, and cardiac arrest than those in the placebo group, although the reductions were relatively small.

Evaluation

Similar abstracts:

• Abstracts: Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Macrovascular disease and systemic sclerosis
• Abstracts: Changes in the medical knowledge of candidates for certification. The mini-CEX (clinical investigation exercise): a preliminary investigation
• Abstracts: Chest pain in cardiac-transplant recipients: evidence of sensory reinnervation after cardiac transplantation. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses
• Abstracts: Amplifying effect of endothelin-1 on serotonin-induced vasoconstriction of human umbilical artery. The nutritional status and treatment of patients with hyperemesis gravidarum
• Abstracts: Listening brief in nursing homes. A singular campaign. Bed choices for physically vulnerable patients

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.